SAN DIEGO, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (Revelation), a clinical-stage life sciences company that is focused on the development of immunologic?based therapies for the prevention and treatment of disease, announced today the site initiation for its Phase 2b viral challenge study (RVL-VRL01) to evaluate the efficacy of intranasal REVTx-99 for the preventive treatment of H3N2 influenza (influenza A) in healthy humans. The study is being conducted in Belgium and is enrolling healthy individuals 18 to 55 years of age.
REVTx-99 activates a nonspecific immune response (innate) which differentiates it from most current treatments focused on a specific immune response (adaptive) potentially allowing for broader use in most infectious viruses. The viral challenge study is the next necessary step in clinical development of REXTx-99 for the treatment of respiratory viral infections. Future development plans include clinical studies in SARS-CoV-2 and its variants, along with other respiratory viruses.
